Epitope-Based Vaccines with the Anaplasma marginale MSP1a Functional Motif Induce a Balanced Humoral and Cellular Immune Response in Mice

PLoS ONE

Volumn 8, Issue 4, 2013, Pages

  Santos, Paula S ^a   Sena, Angela A S ^a   Nascimento, Rafael ^a   Araújo, Thaise G ^a   Mendes, Mirian M ^a   Martins, João R S ^b   Mineo, Tiago W P ^a   Mineo, José R ^a   Goulart, Luiz R ^a,c  

^a FEDERAL UNIVERSITY OF UBERLÂNDIA   (Brazil)

^b Desidério Finamor Veterinary Research Institute FEPAGRO   (Brazil)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL ANTIGEN; BACTERIAL PROTEIN; BACTERIAL VACCINE; BOVINE SERUM ALBUMIN; EPITOPE; FREUND ADJUVANT; IMMUNOGLOBULIN G1 ANTIBODY; IMMUNOGLOBULIN G2A ANTIBODY; MAJOR SURFACE PROTEIN 1; SERYLGLUTAMYLALANYLSERYLTHREONYLSERYLSERYLGLUTAMINYLLEUCYLGLYCYLALANYLGLYCYLGLYCYLGLYCYLSERYLSERYLGLUTAMYLALANYLSERYLTHREONYLSERYLSERYLGLUTAMINYLLEUCYLGLYCYLALANINE; SERYLTHREONYLSERYLSERYLGLUTAMINYLLEUCYLGLYCYLGLYCYLGLYCYLSERYLSERYLTHREONYLSERYLSERYLGLUTAMINYLLEUCYLGLYCYLGLYCYLGLYCYLSERYLSERYLTHREONYLSERYLSERYLGLUTAMINYLLEUCINE; SYNTHETIC PEPTIDE; UNCLASSIFIED DRUG;

ADAPTIVE IMMUNITY; ANAPLASMA MARGINALE; ANAPLASMOSIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY DETECTION; ARTICLE; BLOOD SAMPLING; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE RESPONSE; FEMALE; HUMORAL IMMUNITY; IMMUNOGENICITY; INFECTION PREVENTION; INNATE IMMUNITY; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; POLYMERASE CHAIN REACTION; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; TOXICITY TESTING;

AMINO ACID MOTIFS; ANAPLASMA MARGINALE; ANAPLASMOSIS; ANIMALS; ANTIBODIES, BACTERIAL; BACTERIAL OUTER MEMBRANE PROTEINS; BACTERIAL VACCINES; CATTLE; CYTOKINES; DISEASE MODELS, ANIMAL; EPITOPES; ERYTHROCYTES; FEMALE; IMMUNITY, CELLULAR; IMMUNITY, HUMORAL; IMMUNIZATION; IMMUNOGLOBULIN G; INFLAMMATION MEDIATORS; MICE; PEPTIDES; SPLEEN; TRANSCRIPTION, GENETIC;

ANAPLASMA MARGINALE; ANIMALIA; BOS; BOVINAE; MURINAE; MUS;

EID: 84876006528     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0060311     Document Type: Article

References (51)

1. Kocan KM, de la Fuente J, Blouin EF, Coetzee JF, Ewing SA, (2010) The natural history of Anaplasma marginale. Vet Parasitol 167: 95-107.
2. Kocan KM, de la Fuente J, Guglielmone AA, Melendez RD, (2003) Antigens and alternatives for control of Anaplasma marginale infection in cattle. Clin Microbiol Rev 16: 698-712.
3. Arulkanthan A, Brown WC, McGuire TC, Knowles DP, (1999) Biased immunoglobulin G1 isotype responses induced in cattle with DNA expressing msp1a of Anaplasma marginale. Infect Immun 67: 3481-3487.
4. de Andrade GM, Machado RZ, Vidotto MC, Vidotto O, (2004) Immunization of bovines using a DNA vaccine (pcDNA3.1/MSP1b) prepared from the Jaboticabal strain of Anaplasma marginale. Ann N Y Acad Sci 1026: 257-266.
5. Kawasaki PM, Kano FS, Tamekuni K, Garcia JL, Marana ER, et al. (2007) Immune response of BALB/c mouse immunized with recombinant MSPs proteins of Anaplasma marginale binding to immunostimulant complex (ISCOM). Res Vet Sci 83: 347-354.
6. Kano FS, Tamekuni K, Coelho AL, Garcia JL, Vidotto O, et al. (2008) Induced immune response of DNA vaccine encoding an association MSP1a, MSP1b, and MSP5 antigens of Anaplasma marginale. Vaccine 26: 3522-3527.
7. Tamekuni K, Vidotto MC, Felix SR, Igarashi M, Garcia JL, et al. (2009) Induced immune response of Escherichia coli BL21 expressing recombinant MSP1a and MSP1b proteins of Anaplasma marginale. Braz Arch Biol Technol 52: 113-120.
8. McGarey DJ, Barbet AF, Palmer GH, McGuire TC, Allred DR, (1994) Putative adhesins of Anaplasma marginale: major surface polypeptides 1a and 1b. Infect Immun 62: 4594-4601.
9. Palmer GH, Barbet AF, Cantor GH, McGuire TC, (1989) Immunization of cattle with the MSP-1 surface protein complex induces protection against a structurally variant Anaplasma marginale isolate. Infect Immun 57: 3666-3669.
10. de la Fuente J, Garcia-Garcia JC, Blouin EF, Kocan KM, (2001) Differential adhesion of major surface proteins 1a and 1b of the ehrlichial cattle pathogen Anaplasma marginale to bovine erythrocytes and tick cells. Int J Parasitol 31: 145-153.
11. Tamekuni K, Kano FS, Ataliba AC, Marana ER, Venancio EJ, et al. (2009) Cloning, expression, and characterization of the MSP1a and MSP1b recombinant proteins from PR1 Anaplasma marginale strain, Brazil. Res Vet Sci 86: 98-107.
12. Palmer GH, McElwain TF, (1995) Molecular basis for vaccine development against anaplasmosis and babesiosis. Vet Parasitol 57: 233-253.
13. Vidotto MC, McGuire TC, McElwain TF, Palmer GH, Knowles DP Jr, (1994) Intermolecular relationships of major surface proteins of Anaplasma marginale. Infect Immun 62: 2940-2946.
14. Tebele N, McGuire TC, Palmer GH, (1991) Induction of protective immunity by using Anaplasma marginale initial body membranes. Infect Immun 59: 3199-3204.
15. Brown WC, Palmer GH, Lewin HA, McGuire TC, (2001) CD4(+) T lymphocytes from calves immunized with Anaplasma marginale major surface protein 1 (MSP1), a heteromeric complex of MSP1a and MSP1b, preferentially recognize the MSP1a carboxyl terminus that is conserved among strains. Infect Immun 69: 6853-6862.
16. Allred DR, McGuire TC, Palmer GH, Leib SR, Harkins TM, et al. (1990) Molecular basis for surface antigen size polymorphisms and conservation of a neutralization-sensitive epitope in Anaplasma marginale. Proc Natl Acad Sci U S A 87: 3220-3224.
17. Palmer GH, Waghela SD, Barbet AF, Davis WC, McGuire TC, (1987) Characterization of a neutralization-sensitive epitope on the Am 105 surface protein of Anaplasma marginale. Int J Parasitol 17: 1279-1285.
18. Brown WC, Shkap V, Zhu D, McGuire TC, Tuo W, et al. (1998) CD4(+) T-lymphocyte and immunoglobulin G2 responses in calves immunized with Anaplasma marginale outer membranes and protected against homologous challenge. Infect Immun 66: 5406-5413.
19. Estes DM, Closser NM, Allen GK, (1994) IFN-gamma stimulates IgG2 production from bovine B cells costimulated with anti-mu and mitogen. Cell Immunol 154: 287-295.
20. Sette A, Fikes J, (2003) Epitope-based vaccines: an update on epitope identification, vaccine design and delivery. Curr Opin Immunol 15: 461-470.
21. Santos PS, Nascimento R, Rodrigues LP, Santos FAA, Faria PCB, et al. (2012) Functional epitope core motif of the Anaplasma marginale major surface protein 1a and its incorporation onto bioelectrodes for antibody detection. PLoS One 7: e33045 doi:10.1371/journal.pone.0033045.
22. Sambrook J, Russell DW (2006) Purification of nucleic acids by extraction with phenol:chloroform. Cold Spring Harb Protoc. doi:10.1101/pdb.prot4455.
23. Laemmli UK, (1970) Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227: 680-685.
24. Towbin H, Gordon J, (1984) Immunoblotting and dot immunobinding-current status and outlook. J Immunol Methods 72: 313-340.
25. Coetzee JF, Apley MD, Kocan KM, Rurangirwa FR, Van Donkersgoed J, (2005) Comparison of three oxytetracycline regimes for the treatment of persistent Anaplasma marginale infections in beef cattle. Vet Parasitol 127: 61-73.
26. Blas-Machado U, de la Fuente J, Blouin EF, Almazán C, Kocan KM, et al. (2007) Experimental infection of C3H/HeJ mice with the NY18 isolate of Anaplasma phagocytophilum. Vet Pathol 44: 64-73.
27. de la Fuente J, Lew A, Lutz H, Meli ML, Hofmann-Lehmann R, et al. (2005) Genetic diversity of Anaplasma species major surface proteins and implications for anaplasmosis serodiagnosis and vaccine development. Anim Health Res Rev 6: 75-89.
28. de la Fuente J, Garcia-Garcia JC, Blouin EF, Kocan KM, (2003) Characterization of the functional domain of major surface protein 1a involved in adhesion of the rickettsia Anaplasma marginale to host cells. Vet Microbiol 91: 265-283.
29. McGarey DJ, Allred DR, (1994) Characterization of hemagglutinating components on the Anaplasma marginale initial body surface and identification of possible adhesins. Infect Immun 62: 4587-4593.
30. Palmer GH, Barbet AF, Davis WC, McGuire TC, (1986) Immunization with an isolate-common surface protein protects cattle against anaplasmosis. Science 231: 1299-1302.
31. Sun W, JW IJ, Telford SR 3rd, Hodzic E, Zhang Y, et al (1997) Immunization against the agent of human granulocytic ehrlichiosis in a murine model. J Clin Invest 100: 3014-3018.
32. Onate AA, Cespedes S, Cabrera A, Rivers R, Gonzalez A, et al. (2003) A DNA vaccine encoding Cu,Zn superoxide dismutase of Brucella abortus induces protective immunity in BALB/c mice. Infect Immun 71: 4857-4861.
33. Yip HC, Karulin AY, Tary-Lehmann M, Hesse MD, Radeke H, et al. (1999) Adjuvant-guided type-1 and type-2 immunity: infectious/noninfectious dichotomy defines the class of response. J Immunol 162: 3942-3249.
34. Cantor GH, Pontzer CH, Palmer GH, (1993) Opsonization of Anaplasma marginale mediated by bovine antibody against surface protein MSP-1. Vet Immunol Immunopathol 37: 343-350.
35. Adler H, Peterhans E, Nicolet J, Jungi TW, (1994) Inducible L-arginine-dependent nitric oxide synthase activity in bovine bone marrow-derived macrophages. Biochem Biophys Res Commun 198: 510-515.
36. Stich RW, Shoda LK, Dreewes M, Adler B, Jungi TW, et al. (1998) Stimulation of nitric oxide production in macrophages by Babesia bovis. Infect Immun 66: 4130-4136.
37. Akkoyunlu M, Fikrig E, (2000) Gamma interferon dominates the murine cytokine response to the agent of human granulocytic ehrlichiosis and helps to control the degree of early rickettsemia. Infect Immun 68: 1827-1833.
38. Angulo I, Fresno M, (2002) Cytokines in the pathogenesis of and protection against malaria. Clin Diagn Lab Immunol 9: 1145-1152.
39. Martin ME, Caspersen K, Dumler JS, (2001) Immunopathology and ehrlichial propagation are regulated by interferon-gamma and interleukin-10 in a murine model of human granulocytic ehrlichiosis. Am J Pathol 158: 1881-1888.
40. Lepidi H, Bunnell JE, Martin ME, Madigan JE, Stuen S, et al. (2000) Comparative pathology, and immunohistology associated with clinical illness after Ehrlichia phagocytophila-group infections. Am J Trop Med Hyg 62: 29-37.
41. Dumler JS, Trigiani ER, Bakken JS, Aguero-Rosenfeld ME, Wormser GP, (2000) Serum cytokine responses during acute human granulocytic ehrlichiosis. Clin Diagn Lab Immunol 7: 6-8.
42. Dumler JS, Barat NC, Barat CE, Bakken JS, (2007) Human granulocytic anaplasmosis and macrophage activation. Clin Infect Dis 45: 199-204.
43. Singh RP, Kashiwamura S, Rao P, Okamura H, Mukherjee A, et al. (2002) The role of IL-18 in blood-stage immunity against murine malaria Plasmodium yoelii 265 and Plasmodium berghei ANKA. J Immunol 168: 4674-4681.
44. Li C, Sanni LA, Omer F, Riley E, Langhorne J, (2003) Pathology of Plasmodium chabaudi chabaudi infection and mortality in interleukin-10-deficient mice are ameliorated by anti-tumor necrosis factor alpha and exacerbated by anti-transforming growth factor beta antibodies. Infect Immun 71: 4850-4856.
45. Hamza T, Barnett JB, Li B, (2010) Interleukin 12 a key immunoregulatory cytokine in infection applications. Int J Mol Sci 11: 789-806.
46. Komai-Koma M, Gracie JA, Wei XQ, Xu D, Thomson N, et al. (2003) Chemoattraction of human T cells by IL-18. J Immunol 170: 1084-1090.
47. Berg RE, Crossley E, Murray S, Forman J, (2003) Memory CD8+ T cells provide innate immune protection against Listeria monocytogenes in the absence of cognate antigen. J Exp Med 198: 1583-1593.
48. Raue HP, Brien JD, Hammarlund E, Slifka MK, (2004) Activation of virus-specific CD8+ T cells by lipopolysaccharide-induced IL-12 and IL-18. J Immunol 173: 6873-6881.
49. Pedra JH, Sutterwala FS, Sukumaran B, Ogura Y, Qian F, et al. (2007) ASC/PYCARD and caspase-1 regulate the IL-18/IFN-gamma axis during Anaplasma phagocytophilum infection. J Immunol 179: 4783-4791.
50. Rottenberg ME, Gigliotti-Rothfuchs A, Wigzell H, (2002) The role of IFN-γ in the outcome of chlamydial infection. Curr Opin Immunol 14: 444-451.
51. Eriks IS, Stiller D, Palmer GH, (1993) Impact of persistent Anaplasma marginale rickettsemia on tick infection and transmission. J Clin Microbiol 31: 2091-2096.